指南与共识神经肿瘤

异柠檬酸脱氢酶(IDH)突变型胶质瘤:神经肿瘤学会(SNO)关于诊断、管理与未来方向的共识综述

Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions.
指南 / 共识 · Neuro Oncol · 2023-01-01

该共识综述由神经肿瘤学会(SNO)发布,讨论IDH突变型胶质瘤的当前诊断与管理,并回顾靶向分子治疗和免疫治疗等新疗法,同时讨论当前挑战和未来研究方向。

要点

  • IDH突变型胶质瘤是50岁以下成人中最常见的恶性原发性脑肿瘤。
  • 共识综述涵盖IDH突变型胶质瘤的诊断与管理。
  • 综述还讨论了靶向分子治疗和免疫治疗等新疗法及未来研究方向。

核心结论

  • 该共识综述讨论了IDH突变型胶质瘤的当前诊断与管理,并回顾了靶向分子治疗和免疫治疗等新疗法,同时讨论了当前挑战和未来研究方向。

研究设计与样本

  • 本文为神经肿瘤学会(SNO)发布的共识综述。

主要发现

  • IDH突变型胶质瘤是50岁以下成人中最常见的恶性原发性脑肿瘤,是重要的发病和死亡原因。
  • 近年来在这些肿瘤的分子发病机制和生物学理解方面取得了显著进展,推动了改善其诊断和治疗的多种努力。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Isocitrate dehydrogenase (IDH) mutant gliomas are the most common adult, malignant primary brain tumors diagnosed in patients younger than 50, constituting an important cause of morbidity and mortality. In recent years, there has been significant progress in understanding the molecular pathogenesis and biology of these tumors, sparking multiple efforts to improve their diagnosis and treatment. In this consensus review from the Society for Neuro-Oncology (SNO), the current diagnosis and management of IDH-mutant gliomas will be discussed. In addition, novel therapies, such as targeted molecular therapies and immunotherapies, will be reviewed. Current challenges and future directions for research will be discussed.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Miller JJ, Gonzalez Castro LN, McBrayer S, et al. Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions. Neuro Oncol. 2023. PMID: 36239925. doi:10.1093/neuonc/noac207

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。